Tagged with Switzerland,

Switzerland From its origins in early 20th-century Italy to its present-day role as a trusted partner to leading pharmaceutical players, MUNIT Group has carved a unique space at the intersection of engineering and drug development. With micronization at its core, the company combines proprietary technology, scientific expertise, and strategic foresight to…

Switzerland In a health and wellness landscape crowded with disputable claims and flash-in-thepan trends, A.Vogel stands out for its quiet consistency and scientific conviction. Over the past five years, the Swiss-based natural health company has doubled down on quality, transparency, and long-term vision; from scaling up GMP-certified production and running clinical…

Switzerland Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping evidence-based phytotherapy, from pioneering prescription-grade herbal medicines in Switzerland to launching the Zeller Plus line of preventive supplements. With a…

Switzerland Alexander Salzmann with nearly a decade at Sandoz, reflects on the company’s transition from a Novartis division to an independent, Swiss-listed entity. In this interview, Salzmann discusses the challenges and opportunities of operating a business in the company’s home market Switzerland, and the Sandoz ambition to lead the generics and…

Switzerland From regenerating damaged muscles to rewriting the cell manufacturing playbook, Switzerland’s next wave of biotech innovators is turning regenerative medicine into a precision science. Once considered futuristic, technologies like autologous tissue grafts, gene-edited therapies, and cell-state reprogramming are now gaining real-world traction with Swiss startups at the forefront. These five…

Switzerland Currently supplying high-quality medicines to approximately 1 billion patients around the world annually, few pharmaceutical companies straddle both scale and innovation as deliberately as Viatris. In Switzerland – a market perceived as small in scale, yet rich in complexity – the company is redefining its role, identifying where it can…

Switzerland Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on complex antibody development. Evitria is expanding its technology and global reach to become a key partner in bispecific and engineered…

Switzerland Luc Henry, co-founder and CEO of Limula, speaks about the challenges and opportunities in the field of cell and gene therapy. A chemist by training, Henry’s path from molecular sciences to cancer immunology and ultimately to entrepreneurship reveals how interdisciplinary thinking can catalyse bold innovation. In this conversation, Henry explains…

Switzerland Thomas Bohn has led the Greater Geneva Bern area (GGBa) investment agency for over a decade, shaping Switzerland’s strategy to attract global life sciences firms. He focuses on quality over quantity, targeting high-potential biotech, pharma, and medtech companies and supporting their European growth through sustainable partnerships. Switzerland’s life sciences heritage…

Switzerland Daniel Palmacci, Head of Specialized Modalities at Lonza, combines entrepreneurial vision with deep technical expertise in advanced therapeutics manufacturing. With experience spanning chemical engineering, international operations, and biotechnology development across Europe, the Americas, and Asia, he has played a pivotal role in transforming laboratory discoveries into commercial treatments. In this…

Switzerland Neurim Pharmaceuticals is a research-driven pharmaceutical company dedicated to advancing science in central nervous system disorders, with a strong emphasis on sleep-related conditions. Carolin Hillebrand, Country Manager of Switzerland and Regional Alliance Lead for the German market, shares the company’s recent achievements including the development, regulatory approval, and commercialisation of…

Switzerland Founded in 1971, the Helmut Horten Foundation has steadily evolved from a discreet philanthropic entity into a pivotal force within Switzerland’s medical research landscape. Today, under the leadership of Alain Robert, the Foundation is navigating a strategic transformation, channelling expanded resources into precision oncology, immunology, and emerging priorities like mental…